These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23414513)

  • 1. Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.
    Reichmann WM; LaValley MP; Gagnon DR; Losina E
    BMC Med Res Methodol; 2013 Feb; 13():21. PubMed ID: 23414513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement?
    Wong MY; Day NE; Luan JA; Chan KP; Wareham NJ
    Int J Epidemiol; 2003 Feb; 32(1):51-7. PubMed ID: 12690008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinded sample size re-estimation for comparing over-dispersed count data incorporating follow-up lengths.
    Igeta M; Matsui S
    Stat Med; 2022 Dec; 41(29):5622-5644. PubMed ID: 36148560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size re-estimation in clinical trials.
    Wang P; Chow SC
    Stat Med; 2021 Nov; 40(27):6133-6149. PubMed ID: 34433225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population performance of SEM parceling strategies under measurement and structural model misspecification.
    Rhemtulla M
    Psychol Methods; 2016 Sep; 21(3):348-368. PubMed ID: 26828780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count data.
    Igeta M; Takahashi K; Matsui S
    Biometrics; 2018 Dec; 74(4):1459-1467. PubMed ID: 29579337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian clinical trial design using historical data that inform the treatment effect.
    Psioda MA; Ibrahim JG
    Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size determination for the group comparison of patient-reported outcomes using the Rasch model: impact of a misspecification of the parameters.
    Blanchin M; Guilleux A; Perrot B; Bonnaud-Antignac A; Hardouin JB; Sébille V
    BMC Med Res Methodol; 2015 Mar; 15():21. PubMed ID: 25880670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between statistical power and predictor distribution in multilevel logistic regression: a simulation-based approach.
    Olvera Astivia OL; Gadermann A; Guhn M
    BMC Med Res Methodol; 2019 May; 19(1):97. PubMed ID: 31072299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accounting for the rarity of the disease when designing clinical trials with a focus on pediatric cancers.
    Mauguen A
    Clin Trials; 2022 Jun; 19(3):292-296. PubMed ID: 35232288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.